FDA Approval Insights: Adjuvant Pembrolizumab in RCC

Season 6 Episode 15  ·  Dec 06, 2021, 08:50 PM

Headliner
Share
Subscribe

Dr. Choueiri discusses the significance of the FDA approval of pembrolizumab as adjuvant therapy in renal cell carcinoma and key data from the pivotal phase 3 KEYNOTE-564 trial.

Share
Subscribe
Next
Coombs Previews Anticipated ASH Abstracts in CLL
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air